Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - September 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

AER
Adverse Reaction Report (Adverse Event)
DIN
Drug Identification Number
DIN-HM
Homeopathic Medicine Number
NPN
Natural Product Number
For the month of September 2013
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-00416 All documents on the health and environmental effect D4 and D5 siloxane chemicals. (Jan 1, 2007 to Jun 28, 2010). Disclosed in part 694
A-2011-00046 Information regarding the product Xeomin by Merz Pharmaceuticals GmbH. Disclosed in part 268
A-2011-01253 All documents regarding the Supreme Court decision on INSITE. (Sep 15, 2011 to Dec 22, 2011). Disclosed in part 547
A-2012-00822 Information regarding the product KEVADON, by Wm. S. Merrell Company. Disclosed in part 498
A-2012-01206 Documents related to the applications for Temporary Marketing Authorization for the following products: Red Bull, Monster, 5 hour Energy, Rockstar, NOS, AMP, Full Throttle, Jolt. (Oct 1 2011 to Nov 27, 2012). Disclosed in part 108
A-2012-01656 AERs. Report numbers: 000446835, 000435816, 000443532, 000415106, 000380218, 000435643, 000436650, 000454824, 000437411 and 000440089. Disclosed in part 19
A-2013-00004 All documents considered and/or relied upon by the Pest Management Regulatory Agency (PMRA) in relation to the re-evaluation of Diquat Dibromide as detailed in the Proposed Re-evaluation Decision (PRVD2008-I2) and the Re-evaluation Decision (RVD2010-03). Disclosed in part 446
A-2013-00045 Copies of Ministerial Paragraphs, Question Period notes, media lines and briefing notes created in fiscal year 2012-13 by Health Canada's Marketed Health Products Directorate. Disclosed in part 51
A-2013-00057 Information regarding the following products:
  • Psorinum, NPN 80008212
  • Staphylococcinum, NPN 80032535
  • Streptococcinum, NPN 80008207
  • Tuberculinum, DIN-HM 80006196
  • Tuberculinum Aviare, NPN 80008347
Disclosed in part 152
A-2013-00058 Information regarding the following products:
  • Diphtherinum, NPN 80006760
  • Influenzinum, NPN 80006870
  • Medorrhinum, NPN 80006705
  • Morbillinum, NPN 80006822
  • Pertussinum, DIN-HM 80006597
Disclosed in part 205
A-2013-00059 Information regarding the following products:
  • Psorinum, DIN-HM 80006617
  • Staphylococcinum, NPN 80006641
  • Streptococcinum, NPN 80006680
  • Tuberculinum, NPN 80006656
  • Tuberculinum Bovinum, NPN 80006685
Disclosed in part 201
A-2013-00060 Information regarding the following products:
  • Influenzinum, NPN 80012546, 80012547, 80012548
  • Influenzinum 9ch; Influenzinum; Influenzinum Prevention; Influenzinum PrÚvention, NPN 80012471
  • Medorrhinum, NPN 80018128, 80018129, 80018130
  • Pertussinum, NPN 80018115, 80018119, 80018120
Disclosed in part 255
A-2013-00133 AER. Report number: 000475878. Disclosed in part 5
A-2013-00134 AER. Report number: 000475885. Disclosed in part 4
A-2013-00135 AER. Report number: 000475897. Disclosed in part 4
A-2013-00146 AER. Report number: 000471262. Disclosed in part 2
A-2013-00237 AER. Report number: 000474508. Disclosed in part 3
A-2013-00268 Copies of any documents showing the number of people who died or who suffered significant side effects following clinical trials conducted by individuals/used as guinea pigs to test medications or clinical trials. (Jan 1, 2008 to May 30, 2013). Disclosed in part 5
A-2013-00281 All briefing notes in MECS for the following files: 12-121198-186, 12-118815-389, 12-121216-30 and 12-120254-719. Disclosed in part 18
A-2013-00283 Information regarding the product Adrien Gagnon Sulfate De Glucosamine, Chondroitine & CollagŔne, NPN 80007459 by SantÚ Naturelle (A.G.) LtÚe. Disclosed in part 92
A-2013-00286 List of briefing notes prepared for the Minister. (Dec 12, 2012 to Jun 5, 2013). Disclosed in part 25
A-2013-00287 Information regarding the product Adrien Gagnon Sulfate De Glucosamine & CollagŔne Type II, NPN 80003045 by SantÚ Naturelle (A.G.) LtÚe. Disclosed in part 162
A-2013-00315 All documents showing the number of people who died after ingesting a cough syrup (over-the-counter) in the hours following ingestion or within 10 days following ingestion. Disclosed in part 9
A-2013-00318 AERs for the following products/report numbers: Adalat XL (000484375), Avelox (000482247, 000483511, 000486644, 000488577), Cipro XL (000483019), Gadovist (000483503), Magnevist (000483660), Mirena (000484186), Xarelto (000487509, 000485248). Disclosed in part 19
A-2013-00336 AER for the product Busulfan. Report number: 000462365. Disclosed in part 30
A-2013-00337 AER for the product Busulfan. Report number: 000462359. Disclosed in part 31
A-2013-00340 Current list of all substances covered by the Controlled Drugs and Substances Act and related Schedules and any documents with information pertaining to how the list is managed and updated. All disclosed 1,869
A-2013-00367 AERs for the product Humira. Report numbers: 000400618, 000429648, 000433370, 000384389, 000440408, 000413005, 000410653, 000411416, 000422466, 000425803 and 000413563. Disclosed in part 62
A-2013-00368 AERs for the product Norvir. Report numbers: 000415677, 000386469, 000398700, 000398703, 000441227 and 000439841. Disclosed in part 25
A-2013-00373 AERs for the product Norvir. Report numbers: 000471866 and 000465552. Disclosed in part 28
A-2013-00385 AERs. Report numbers: 000402025, 000405319, 000406496, 000425529, 000426118, 000434526, 000437292, 000443502, 000443735, 000450146, 000451204, 000456475, 000459530, 000468424, 000477658, 000480318, 000481104 and 000484215. Disclosed in part 27
A-2013-00389 AERs for the following products/report numbers: Aspirin (000491551, 000491185, 000490723, 000490126, 000490041, 000490008, 000489883, 000486635, 000486344, 000473956, 000479092), Aleve (000467996), Canesten (000473269), Canesoral (000487784, 000467098), Maxidol (000484019, 000475554), One a Day (000478916). Disclosed in part 69
A-2013-00429 List of all Briefing notes prepared for the Health Minister or the Deputy Minister during the month June 2013. Disclosed in part 21
A-2013-00435 Results of any linguistic profile assessments taken with regards to any and all linguistic profile changes to positions already staffed or vacant in the Office of Regulatory Affairs, in the Biologics and Genetic Therapies Directorate, Health Products and Food Branch. (Apr 1, 2012 to Jul 31 2013). Disclosed in part 5
A-2013-00436 AER. Report number: 000503542. Disclosed in part 5
A-2013-00503 Contract reference number 4500287701 dated March 4, 2013 (described as being for dental services and an overall contract value of $1,065,000). Disclosed in part 34
A-2013-00515 A listing of the Access to Information requests submitted to Health Canada. (Jul 1, 2013 to Jul 31, 2013). Disclosed in part 9
A-2013-00520 Briefing material and public communication material related to folic acid fortification of white flour and potential amendment of the Food and Drug Regulations. (Jan 1, 2008 to Dec 31, 2012). No records exist 0
A-2013-00521 AER for the product Cyclomen. Report number: 000511177. Disclosed in part 1
A-2013-00522 AER for the product Calcitonin. Report number: 000501782. Disclosed in part 2
A-2013-00523 AER for the product Clomiphene Citrate. Report number: 000498994. Disclosed in part 1
A-2013-00528 AER for the product Enoxaparin Sodium. Report number: 000510907. Disclosed in part 1
A-2013-00536 AER for the product Docetaxel. Report number: 000502352. Disclosed in part 2
A-2013-00537 AER for the product Docetaxel. Report number: 000491484. Disclosed in part 1
A-2013-00542 AER for the product Dronedarone. Report number: 000510992. Disclosed in part 1
A-2013-00554 Information pertaining to losses and thefts reports for the product BuTrans. (Jan 1, 2013 to Jul 31, 2013). All disclosed 1
A-2013-00555 Information pertaining to losses and thefts reports for the product Biphentin. (Jan 1, 2013 to Jul 31, 2013). All disclosed 3
A-2013-00556 Information pertaining to losses and thefts reports for the product Dilaudid. (Jan 1, 2013 to Jul 31, 2013). All disclosed 4
A-2013-00557 Information pertaining to losses and thefts reports for the products OxyNeo or Oxycontin. (Jan 1, 2013 to Jul 31, 2013). All disclosed 1
A-2013-00558 Information pertaining to losses and thefts reports for the product Hydromorph Contin. (Jan 1, 2013 to Jul 31, 2013). All disclosed 9
A-2013-00560 Information pertaining to losses and thefts reports for the product Targin. (Jan 1, 2013 to Jul 31, 2013). All disclosed 1
A-2013-00561 Information pertaining to losses and thefts reports for the product OxyNEO. (Jan 1, 2013 to Jul 31, 2013). All disclosed 5
A-2013-00562 Information pertaining to losses and thefts reports for the product Oxycontin. (Jan 1, 2013 to Jul 31, 2013). All disclosed 1
A-2013-00563 Information pertaining to losses and thefts reports for the products MS Contin, MS-IR, Oxy-IR. (Jan 1, 2013 to Jul 31, 2013). All disclosed 3
A-2013-00570 The overall numbers of Valid Licenses and Production Sites that have been authorized to Produce Cannabis (marihuana) by Health Canada under the Marihuana Medical Access Program within the City of Surrey, British Columbia. (Oct 31, 2011 to Aug 1, 2013). All disclosed 1
A-2013-00571 The civic addresses of all Production Sites that have been authorized to Produce Cannabis (marihuana) by Health Canada under the Marihuana Medical Access Program within the City of Surrey, British Columbia as of August 1, 2013. No records exist 0
A-2013-00572 The total number of Valid Licenses and Production Sites that have been authorized to Produce Cannabis (marihuana) by Health Canada under the Marihuana Medical Access Program within the province of British Columbia. (Aug 1, 2010 to Aug 1, 2013). All disclosed 1
A-2013-00576 AER for the product Canesten. Report number: 000512095. Disclosed in part 2
A-2013-00577 AER for the product Canesoral. Report number: 000512095. Disclosed in part 2
A-2013-00578 AERs for the product Flintstones. Report numbers: 000488812 and 000499272. Disclosed in part 2
A-2013-00579 AERs for the product One A Day. Report numbers: 000488847 and 000507799. Disclosed in part 2
A-2013-00592 All documents related to the communications/meetings between representatives of Imperial Oil Limited and Health Canada. Jan 8, 2010 (Communication report 16851-139082); Jan 13, 2010 (Communication report 16851-139085); Mar, 18, 2011 (Communication report 16851-171039); and Jul 27, 2011 (Communication report 16851-177686). No records exist 0
A-2013-00602 Documents regarding the criteria that were used to determine the list of scientific papers Health Canada provided to the Royal Society of Canada, Expert Panel to review literature pertaining to the Safety Code 6. No records exist 0
A-2013-00605 AER for the product Zuacta. Report number: 000489277. Disclosed in part 1
A-2013-00606 AER for the product Oxaliplatin. Report number: 000510448. Disclosed in part 2
A-2013-00607 AER for the product Insulin Glargine. Report number: 000492165. Disclosed in part 1
A-2013-00610 AER for the product Oxaliplatin. Report number: 000511222. Disclosed in part 2
A-2013-00611 AER for the product Metronidazole/nystatin. Report number: 000490436. Disclosed in part 1
A-2013-00612 AER. Report number: 000487615. Disclosed in part 1
A-2013-00613 AER for the product Hydrochlorothiazide-ibesartan. Report number: 000507326. Disclosed in part 1
A-2013-00614 AER for the product Furosemide. Report number: 000510394. Disclosed in part 2
A-2013-00617 Brand names of the 544 retail samples tested for the study 'Detection of Cyclospora, Cryptosporidium, and Giardia in ready-to-eat packaged leafy green in Ontario, Canada' as well as test results for each retail brand tested. No records exist 0
A-2013-00620 All audits and evaluations of Mental Health Service Providers under the Non Insured Health Benefits Program done in relation to a notice of proposed procurement (attached) posted on Merx.com on 2013-02-07 (solicitation number 10020112950). No records exist 0
A-2013-00644 AER for the product Demerol. Report number: 000496363. Disclosed in part 2
A-2013-00683 AERs. Report numbers: 000493041, 000507919, 000512040, 000500675, 000503127, 000507791 and 000509099. Disclosed in part 7